Fig. 6

Study flowchart. The study was performed in multicenter cohorts, including TCGA-BC, GSE22220, GSE73002, GSE41922, and in-house clinical exosome cohorts. Genome instability-derived miRNAs signature (miGISig) was identified in the discovery cohort. The miGISig was applied to an internal validation cohort and multiple external validation cohorts to verify its value in prognosis and diagnosis of BC. The effects of the miGISig on BC growth were investigated using the in vitro functional assays. BC breast cancer, GI Genome instability